Revenue
2019
2020
2021
2022
2023
2024
Benitec Biopharma Inc. (BNTC)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $75,000 | $73,000 | $59,000 | $97,000 | $11.6M |
| Research & development | $18.3M | $15.6M | $12.8M | $11.3M | $7.0M | $3.0M | $4.6M |
| Operating expenses | $41.8M | $22.5M | $19.2M | $17.9M | $13.7M | $8.4M | $9.6M |
| Operating income | −$41.8M | −$22.5M | −$19.1M | −$17.9M | −$13.6M | −$8.3M | $2.6M |
| EBITDAderived | −$41.7M | −$22.4M | −$18.9M | −$17.7M | −$13.4M | −$8.1M | $2.7M |
| Net income | −$37.9M | −$21.8M | −$19.6M | −$18.2M | −$13.9M | −$8.3M | $2.6M |
| Basic EPSper diluted share | -$1.05 | -$1.22 | -$14.12 | -$37.88 | -$3.23 | -$8.10 | $3.05 |
| Diluted EPSper diluted share | -$1.05 | -$1.22 | -$14.12 | -$37.88 | -$3.23 | -$8.10 | $3.05 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 29, 2025Form 4 | Cowen Aaron +3Director,TenPercentOwner | BuyCommon stock, par value $0.0001 per share · indirect | 11.6K | $13.44 | $155.7K | 1.85M |
| Dec 29, 2025Form 4 | Cowen Aaron +3Director,TenPercentOwner | BuyCommon stock, par value $0.0001 per share · indirect | 65.8K | $13.44 | $884.4K | 9.70M |
| Dec 26, 2025Form 4 | Cowen Aaron +3Director,TenPercentOwner | BuyCommon stock, par value $0.0001 per share · indirect | 2.5K | $13.10 | $33.0K | 1.84M |
| Dec 26, 2025Form 4 | Cowen Aaron +3Director,TenPercentOwner | BuyCommon stock, par value $0.0001 per share · indirect | 14.3K | $13.10 | $187.6K | 9.63M |
| Dec 23, 2025Form 4 | Cowen Aaron +3Director,TenPercentOwner | BuyCommon stock, par value $0.0001 per share · indirect | 7.4K | $12.85 | $95.1K | 1.83M |